Rhythm's bivamelagon cut BMI and hunger scores in Phase 2 trial for hypothalamic obesity, prompting plans to discuss Phase 3 ...

For years, people living with obesity have been given the same basic advice: eat less, move more. But while this mantra may ...

Obesity in itself is not a contraindication to radical prostatectomy, but it remains a risk factor for poor overall survival. Although obesity increases the technical complexity of radical ...

Bivamelagon achieved BMI reductions in patients with acquired hypothalamic obesity of -9.3% and -7.7% in 600mg and 400mg cohorts, respectively, at 14 weeks -- -- Post-hoc analysis showed BMI reduction ...

A GLP-1/glucagon dual agonist conferred weight loss of up to 12.55% at 32 weeks for adults with overweight or obesity, ...

Rhythm Pharma (RYTM) stock gains as the company's experimental therapy bivamelagon shows promise in Phase 2 trial for rare acquired hypothalamic obesity. Read more here.

To improve access to care, many professional organizations have advocated for classifying obesity as a disease. However, the ...

Understanding the link between obesity, fatty liver disease and kidney stones provides a new perspective on prevention and ...

Obesity was significantly more prevalent in Black and Hispanic children and adolescents compared with their non-Hispanic White peers and was potentially exacerbated by the COVID-19 pandemic, a study ...

About 1 in 5 classified as overweight based on BMI alone considered to have obesity according to European society definition.

The "Reduce Size, Reduce Disease" project aims to raise awareness that "Obesity is a disease" requiring medical attention, ...

A new British Nutrition Foundation review finds that most UK women of reproductive age fall short of key nutrients before and ...